From our survey
Speed, privacy and group branding are what ads assume people want; the survey ranking tells a plainer story about coverage and distance.
There is a picture of the typical person seeking newer depression treatment that shows up in a lot of advertising. They are in a hurry. They want something cutting-edge. They care about discretion above all. And they are drawn to clinics that speak to their specific group.
Then we asked 443 real people across ten Midwest states, Missouri among them, and that picture mostly fell apart. Here are five common beliefs about what people want, checked against what they told us. Each number is final; Pollfish has validated them.
Each of our respondents chose two things a ketamine or esketamine clinic must offer. Insurance acceptance topped the tally at 85 percent, and a location near home placed second at 43 percent. FDA approval took 27 percent and rapid results 24 percent; just 11 percent wanted discretion, and 10 percent a clinic focused on veterans or first responders. With two picks apiece, the totals exceed 100.
Speed is appealing, and depression wears people down. But when forced to choose, only about a quarter of respondents spent one of their two picks on fast results. Coverage was chosen more than three times as often.
The survey's tradeoff question tells the same story from another angle. Given insurance with extra paperwork or cash with less, just over half of respondents went with insurance, and the rest split roughly evenly between paying and indecision. Most people are prepared to wait for care they can afford.
There is a practical reason to be wary of speed as a selling point anyway. No provider can promise how quickly, or whether, a particular person will respond. Only a clinician familiar with your history can speak to that.
Stigma around mental health care is real, and it has not vanished in Missouri. But as a deciding factor in choosing a provider, privacy ranked near the bottom, picked by 11 percent. That is roughly one respondent in nine.
This does not mean people are indifferent to discretion. It more likely means that when you only get two priorities, paying for care and getting to care come first. If privacy matters a lot to you, it is still fair to ask a provider about waiting areas, treatment rooms, and how they communicate. Just do not let a clinic's emphasis on discretion distract you from whether it takes your plan.
Clinics sometimes market heavily to veterans and first responders, and there are good reasons to. About 7 percent of our respondents, 29 of 443, have served in the military or as first responders, and many more have a family member who has. But only 10 percent chose specialization in veterans or first responders as a top-two factor.
For someone who has served, experience with trauma and military culture can genuinely matter, and it is worth asking about. But the survey suggests that for most people, a specialty label does not outweigh coverage and distance.
This one is tricky, because the ranking seems to support it. FDA approval finished at 27 percent in the two-pick question, barely ahead of speed. But on its own scale, approval was a big or deciding factor for 59 percent of respondents.
The likeliest reading is that approval matters to most people, but when they could only choose two things, they spent those picks on coverage and location. Some may also assume that anything covered must be approved.
That assumption deserves care. Spravato, the esketamine brand, won approval for depression that has outlasted other treatment, and certified sites alone may supervise it. Ketamine by IV infusion or through at-home programs is used off-label for depression. They are different. If approval matters to you, ask which one a provider offers.
Our respondents ranked a nearby provider second, at 43 percent, far ahead of everything except coverage. In Missouri, that makes sense. The distance between a rural county and the nearest certified site can be long, and even suburban drives add up.
For esketamine, distance weighs more than usual. After every session there are at least two hours of monitoring, and driving is off-limits until the following day. That means a companion, making the round trip, multiple times. A covered site that is too far to reach regularly may not work in practice.
MO HealthNet members can ask their plan about rides to appointments, which can make a distant covered site workable. A plain Missouri-friendly primer from Brain Recovery Centers covers esketamine costs and coverage on the covered route.
Set the myths aside and the survey describes someone quite practical. They want a provider their plan pays for. They want it within reach. They care about approval and results, but not above the basics. And they are willing to handle paperwork to get there.
They also know who they want to hear it from. In our poll, 74 percent of respondents said their doctor's word would get them to try it, and 56 percent planned to start in primary care. Ads persuaded almost no one, just 2 percent of respondents.
This is market research and general information, not medical advice. Esketamine has a narrow approval, it does not fit everyone, and outcomes cannot be promised.
If you are in immediate distress, skip the provider list. Anywhere in Missouri, text or phone 988; Suicide and Crisis Lifeline counselors answer free and in confidence, whatever the hour.
Pollfish survey 395586438 stopped fieldwork on June 23, 2026, by which point 443 panelists between 18 and 64 had completed it, living in Indiana, Missouri, Minnesota, Oklahoma, Nebraska, Ohio, Iowa, Kansas, Illinois and Wisconsin. The provider item was choose-two. Figures cover the whole sample, and validation is finished. Our publisher requested and paid for the study.